BioVisible (founded 2006) is specialised in fast detection and identification of micro-organisms using molecular biological techniques.
Scope; “Research, development, analysis services, production and commercialisation of Molecular Microbial Diagnostics for detection and identification of microorganisms”.
The following activities belong to the core business activities of BioVisible:
(1) Client specific research activities on contract basis
(2) Development and sales of molecular, biological testkits, -systems and products for the detection and identification of micro-organisms.
(3) Routine analysis for third parties.
(4) Client specific implementation of developed tests & training.
RiboTechnologies Products
BioVisible sells molecular, biological testkits under the name RiboTechnologies with world-wide sales. Focus areas are intestinal micro-flora diagnosis, sepsis and environmental diagnosis. New products are developed in-house and in close cooperation with international universities and innovative companies in order to rapidly expand our business. RiboTechnologies has direct sales and a worldwide network of distributors.
BioVisible R&D
Focus is on biodefense and intestinal micro-flora applications.
Business model
BioVisible develops, ‘tailor-made’, advanced diagnostic tests based on DNA technology in the R&D unit. Based on the R&D developments BioVisible offers Molecular Diagnostic analysis services, mostly for the analysis of intestinal microflora and BioVisible manufactures and sells Molecular Diagnostic assays. Products are sold under the trade name RiboTechnologies®. The business model is based on a cycle where developments and questions from the market induce new developments in the R&D unit.
Business model
If you have any questions or you wish to receive more information please do not hesitate to contact us. For discussion of your specific requests please contact Dr. M.E. van der Rest: m.rest@biovisible.com
BioVisible starts a new analysis service using the Mitox™ DNA - Mitochondrial toxicity assay to measure simultaneously the nuclear DNA and mitochondrial RNA content of the cell. This assay can be used as a biomarker for toxicity and/or efficacy of antiviral treatment.
This analysis service is offered in collaboration with Primagen. Click Logo for preliminary website.
Did you know; The first full moon to occur on the winter solstice, Dec. 22, commonly called the first day of winter, happened in 1999. Since a full moon on the winter solstice occurred in conjunction with a lunar perigee (point in the moon's orbit that is closest to Earth), the moon appeared about 14% larger than it does at apogee (the point in it's elliptical orbit that is farthest from the Earth). Since the Earth is also several million miles closer to the sun at that time of the year than in the summer, sunlight striking the moon was about 7% stronger making it brighter. Also, this was the closest perigee of the Moon of the year since the moon's orbit is constantly deforming. In places where the weather was clear and there was a snow cover, even car headlights were superfluous